Immunocore Holdings plc
NASDAQ:IMCRBiotechnology
+$0.18 today
- Market cap
- $1.42B
- Beta
- 0.75
- P/E (TTM)
- -77.5
- EPS (TTM)
- -$0.37
Volume 0.30M
Average 0.40M
IMCR Accounts Receivables
Cash effect of the change in amounts owed by customers; growing receivables consume cash.
Immunocore Holdings plcNASDAQ: IMCR
Accounts Receivables · Q1 FY2026 · quarter ended Mar 2026
Accounts receivables turns negative
Q1 FY2026 accounts receivables was -$7.92M, compared with $836K a year earlier. Trailing-twelve-month accounts receivables was -$16.59M. Over 3 fiscal years it compounded at -40.8% a year.
Context
- Accounts receivables amounted to 1.8% of revenue in FY2025, down 3.1 pp from a year earlier.
- Accounts receivables grew in size in 0 of the last 3 fiscal years.
- FY2025 was the smallest annual figure in the 4 fiscal years shown.
What to watch
Whether quarterly accounts receivables holds near -$7.92M or moves back toward the trailing-twelve-month quarterly average of -$4.15M.
Sources:Cash FlowText generated from reported figures; not investment advice.
Accounts Receivables history
Mixed currencies · from the cash flow
- Latest · FY2025
- (5.46M) USD
- Year-over-year change
- +55.8%
| Period | Period end | Accounts Receivables | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | (5.46M) | +55.8% |
| FY2024 | 2024-12-31 | (12.35M) | — |
| FY2023 | 2023-12-31 | (14.14M) | +46.2% |
| FY2022 | 2022-12-31 | (26.26M) | -440.1% |
| FY2021 | 2021-12-31 | (4.86M) | — |
Accounts Receivables vs competitors
How IMCR compares with its peers on the latest reported figures
- Peers report in different currencies, so accounts receivables is compared through growth and share of revenue rather than absolute size.
- Its year-over-year change of +211.8% is the 2nd highest of 9, against a peer median of +58.2%.
- Accounts receivables amounts to 4.3% of revenue for IMCR, versus a peer median of 9.2%.
| Company | Period | LTM | YoY | 3-year CAGR | % of revenue |
|---|---|---|---|---|---|
| LTM Jun 2026 | €1.89B EUR | +210.6% | -38.0% | 71.6% | |
| LTM Mar 2026 | $35M USD | +401.4% | — | 161.9% | |
| LTM Sep 2026 | $21.58M USD | -22.5% | — | 11.8% | |
| LTM Mar 2026 | $16.59M USD | +211.8% | -40.8% | 4.3% | |
| LTM Jun 2026 | $12M USD | -7.7% | -76.6% | 10.3% | |
| LTM Jun 2026 | $8.54M USD | +12.9% | -8.0% | 8.1% | |
| FY2025 | A$2.52M AUD | -518.5% | +3.8% | 49.9% | |
| LTM Mar 2026 | €1.5M EUR | +138.9% | -18.5% | 4.0% | |
| LTM Mar 2026 | $117K USD | +103.5% | -41.7% | 0.1% | |
| LTM Dec 2025 | $0 USD | — | -50.9% | 0.0% | |
| FY2025 | €0 EUR | — | — | 0.0% | |
| Peer median (excluding IMCR) | — | +58.2% | -38.0% | 9.2% | |
Competitors are the stored peer set for IMCR. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Cash Flow Statement
Metric | FY2021 Dec 2021 · GBP | FY2022 Dec 2022 · GBP | FY2023 Dec 2023 · GBP | FY2024 Dec 2024 · USD | FY2025 Dec 2025 · USD |
|---|---|---|---|---|---|
| Net Income | (180.03M) | (52.54M) | (34.32M) | (51.09M) | (26.42M) |
| Depreciation & Amortization | 7.59M | 5.34M | 3.24M | 4.2M | 2.43M |
| Deferred Income Tax | (12.69M) | (3.53M) | 0 | 0 | 11M |
| Stock-Based Compensation | 48.89M | 32.89M | 25.69M | 34.19M | 0 |
| Change in Working Capital | (21.96M) | (24.17M) | 4.58M | 45.13M | (6.92M) |
| Accounts Receivables | (4.86M) | (26.26M) | (14.14M) | (12.35M) | (5.46M) |
| Inventory | 0 | 0 | 0 | 0 | 0 |
| Accounts Payables | 1.47M | 4.91M | 2.08M | 7.27M | (1.83M) |
| Other Working Capital | (18.57M) | (2.81M) | 16.64M | 50.21M | 366K |
| Other Non-Cash Items | 15.09M | (7.19M) | 3.14M | (6.38M) | 11.94M |
| Operating Cash Flow | (143.11M) | (49.21M) | 2.33M | 26.06M | (7.97M) |
| Capital Expenditures | (1.39M) | (2.2M) | (4.29M) | (5.17M) | (3.23M) |
| Acquisitions (Net) | 0 | 0 | 0 | 0 | 0 |
| Purchases of Investments | 0 | 0 | 0 | (350M) | (22.32M) |
| Sales of Investments | 0 | 0 | 0 | 0 | 13.39M |
| Other Investing Activities | 106K | 6K | (925.46K) | 44K | 0 |
| Investing Cash Flow | (1.28M) | (2.2M) | (4.29M) | (355.13M) | (12.16M) |
| Debt Repayment | 0 | 0 | 0 | 352.5M | 0 |
| Common Stock Issued | 286.89M | 139.52M | 0 | 6.8M | 9.2M |
| Common Stock Repurchased | 0 | 0 | 0 | 0 | 0 |
| Dividends Paid | 0 | 0 | 0 | 0 | 0 |
| Other Financing Activities | 1.3M | 5.93M | 27.18M | (15.42M) | 0 |
| Financing Cash Flow | 288.19M | 145.44M | 27.18M | 343.88M | 9.2M |
| Effect of Forex Changes | 625K | (12.65M) | 6.56M | (1.71M) | 19.81M |
| Net Change in Cash | 144.42M | 81.39M | 31.78M | 13.11M | 8.89M |
| Free Cash Flow | (144.49M) | (51.41M) | (1.97M) | 20.89M | (11.2M) |
Immunocore Holdings plc
NASDAQ:IMCR
Intrinsic Alpha fair value
Locked
Current Price
$27.51
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.